Oberon began publishing research on Renalytix, giving investors another source of company information. The story reports no rating or change in sales or results, so it does not change Renalytix's outlook.
Investors now have another source discussing Renalytix's diagnostic business. The story reports no rating, sales change, or new company results, so it gives no clear reason to change the company's outlook.
Follow Renalytix plc (RENX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RENX